The Young Genetic Stroke Alliance: A Natural History with Biomarkers of Hereditary Cerebrovascular Disorders

Dr. Musolino and Dr. Gould are working in parallel on developing gene therapies to help patients with COL4A1 and COL4A2 variants.* As part of the Young Genetic Stroke Alliance efforts, this ongoing study at MGH follows patients with Gould Syndrome to learn how the condition changes over time, what to measure, and who may benefit from future treatments.

This study will play a crucial role in clinical trial readiness by establishing clinical biomarkers that may serve as future clinical trial endpoints.

at a glance

  • Who can join: anyone with a confirmed COL4A1 or COL4A2 variant (including VUS) in the US or internationally

  • Where: Remotely from anywhere, or in person at Massachusetts General Hospital (MGH) in Boston, Massachusetts, USA

  • What's involved:

    • Sharing medical records and prior imaging

    • (optional) blood and skin samples at MGH

  • Follow-up: yearly or sooner, depending on the person

  • Cost: none

You're welcome to join this study even if you're already in the UCSF study.

*Please note that participation in the natural history study will not impact your medical care. If you are interested in scheduling a clinical appointment (second opinion) at MGH, please ask the research coordinator or contact your PCP for a referral.

webinars

frequently asked questions